Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate dehydrogenase (LDH). The purpose of this study is to determine whether an intermittent adaptive dosing of vemurafenib and cobimetinib may be superior to standard, continuous …

measurable disease
unresectable melanoma
systemic therapy
cobimetinib
braf v600 mutation
  • 10 views
  • 04 Oct, 2022
  • 1 location
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation …

measurable disease
malignant melanoma of skin
solid tumour
cancer
  • 43 views
  • 25 May, 2022
  • 13 locations
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.

LKB1
measurable disease
systemic therapy
metastatic melanoma
growth factor
  • 34 views
  • 04 Oct, 2022
  • 19 locations
Imaging Modalities for Melanoma Screening and Diagnosis

This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.

shave biopsy
nevus
Accepts healthy volunteers
skin lesion
skin cancer
  • 43 views
  • 21 Oct, 2022
  • 1 location
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

pembrolizumab
nbtxr3
nivolumab
cancer
  • 13 views
  • 07 Oct, 2022
  • 7 locations
TH1902 in Patients With Advanced Solid Tumors

Open label first-in-human study of TH1902 in solid cancer, with 2 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist. Part 2 (expansion): selected patient …

human immunodeficiency virus
measurable disease
hysterectomy
cancer treatment
oophorectomy
  • 0 views
  • 10 Jul, 2022
  • 6 locations
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

interleukin 2
mammogram
measurable disease
  • 23 views
  • 04 Oct, 2022
  • 8 locations
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread to the brain.

brain metastases
neutrophil count
ocular melanoma
measurable disease
cytotoxic t-lymphocyte antigen 4
  • 0 views
  • 01 Oct, 2021
  • 2 locations
A Phase 2, Multicentre, Open-Label Study of SCIB1 in Patients With Advanced Unresectable Melanoma Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

The purpose of this study is to find out if a new treatment cancer vaccine called SCIB1 can be used safely when added to either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma (skin cancer). The study will also look to see …

measurable disease
advanced melanoma
metastatic melanoma
unresectable melanoma
yervoy
  • 21 views
  • 24 Oct, 2022
  • 5 locations
Minimal SN Tumor Burden

The purpose of this registry is to collect data in order to discover whether melanoma patients with minimal SN tumor burden should undergo a complete lymph node dissection (CLND) or not. Currently, if a patient has a positive (or metastatic) SN, this patient will be offered a CLND, which is …

metastasis
malignant melanoma of skin
cancer
  • 57 views
  • 22 Jan, 2021
  • 17 locations